Novo Nordisk announced Monday that U.S. patients can now get a month's supply of Ozempic, the blockbuster diabetes drug, for ...

Over the past year, Eli Lilly ($LLY) stock has tumbled almost 24%, pressured by regulatory concerns, disappointing trial ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for ...

Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver ...

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

The company said Friday that it received FDA approval for a new Wegovy indication as a treatment of a fatty liver disease known as metabolic dysfunction-associated steatohepatitis, or MASH, in adults ...

To provide a brief background, the TRAILBLAZER-ALZ 2 LTE study was a Phase 3, double-blind extension of the original ...

Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Eli Lilly and Company (NYSE:LLY)’s pipeline has been advancing, thanks to positive study results in oncology and ...